

**S2 Table:** Characteristics of allo-HSCT patients, donors, and transplantation procedures.

<b>Characteristics</b>	<b>Patient 1</b>	<b>Patient 2</b>	<b>Patient 3</b>
Patient age, years	30	43	18
Patient sex	female	female	female
Underlying disease	SAA	AML	SAA
Donor sex	male	female	male
CMV serostatus			
Donor / Recipient	neg / neg	neg / neg	neg / neg
Donor type	unrelated	unrelated	unrelated
HLA match	matched	matched	matched
Graft source	PBSCs	PBSCs	BM
Conditioning regimen	RIC	RIC	RIC
GvHD prophylaxis	ATG-CyA-Sir	ATG-CyA-MMF	ATG-CyA-Sir
Neutrophil engraftment, day	105	23	60
aGvHD	grade II	grade I	none
aGvHD onset, day	115	14	-
HHV-6 treatment	foscarnet, cidofovir	none	none
Viral coinfection	EBV	EBV, adenovirus	adenovirus

Abbreviations: neg, negative; SAA, severe aplastic anemia; AML, acute myeloid leukemia; HLA, human leukocyte antigen; PBSCs, peripheral blood stem cells; BM, bone marrow; RIC, reduced intensity conditioning; ATG, anti-thymocyte globulin; CyA, cyclosporine A; Sir, Sirolimus; aGVHD, acute graft-versus-host disease; EBV, Epstein-Barr virus.